Kamran Tahamtanzadeh, Chief Executive Officer: As CEO, Kamran is responsible for defining and implementing corporate strategy, and for developing, leading and managing key partnership, investor and strategic relationships. Previously, Kamran was CEO of EpiCELONA, LLC a Bay-Area based healthcare focused management consultancy and investor relations firm, Chief Commercial Officer at Exosomics S.p.A. ( Acquired by Lonza Therapeutiucs), and founding CEO at PrognosDx Health, Inc, a pioneering precision medicine- Epigenetics platform company addressing molecular profiling challenges in the field of oncology. Prior to these roles, Kamran held various corporate and business development roles within translational medicine field.  Kamran is an internationally recognized business executive with a comprehensive domain knowledge in the Proteomics field. Kamran holds a B.A. degree in Molecular Genetics from University of Cal at Berkeley.

David Ure, Chairman and Founder: Mr. Ure is Inanovate’s founder and Chairman; he is also a co-inventor of the Longitudinal Assay Screening technology. He works closely with Kamran (Inanovate CEO) to help coordinate all aspects of the Company’s execution, including the development and implementation of Inanovate’s products and operating infrastructure. Mr. Ure was previously an entrepreneur in the financial consulting industry and has spent the last twenty years in executive roles within Life Science and management consulting industries. Mr. Ure holds a Bachelor of Science with honors in Astrophysics, a Master of Science with Distinction in Radiation Physics from the University of Birmingham, U.K., and an MBA Summa Cum Laude, from Babson College, US.

Aaron Harmon Ph.D., General Manager & Director of Quality: Dr. Harmon coordinates, leads, and implements Inanovate’s operational strategy. In addition, he is building and implementing the Quality Management System to ensure Inanovate is compliant to the FDA’s Design Control approach and GMP manufacturing. He has over a decade of experience in product development and quality systems. Dr. Harmon holds a Ph.D. in Biological Sciences from South Dakota State University and is active in the community if providing Quality Assurance education through the University of South Dakota.

Greg Votaw, Vice President of Engineering: Mr. Votaw is responsible for the design, manufacture, and optimization of Inanovate’s Bio-ID systems. Mr. Votaw has over 20 years’ experience developing and implementing automation systems for the pharmaceutical industry and managing projects from concept through R&D and installation at research sites worldwide. He is a specialist in microfluidics and automation systems with six issued patents and peer-reviewed papers. Mr. Votaw holds an AE in Electronics Engineering; and was three-time recipient of Scientific Excellence Award at GlaxoSmithKline.

Casey Wright, Ph.D. Vice President of Assay Development: Dr. Wright oversees the development, optimization, and validation of all assays in process for the Bio-ID platform. He has 16 years of experience that spans clinical research and assay development in both the academic and industrial setting. Dr. Wright received his Ph.D. from Colorado State in Biomedical Science.

James Nelson, Ph.D. Director of Platform Development: Dr. Nelson is co-inventor of the Longitudinal Assay Screening technology. He leads the Bio-ID development. Dr. Nelson has over 16 years experience in developing and establishing advanced technologies for biomolecule screening, including 10 years as Manager of Technology Development at GlaxoSmithKline where he ran an interdisciplinary team on the development and optimization of next generation multiplexing technologies. Dr. Nelson holds a Bachelor of Science in Chemistry from the Florida State University and a Ph.D. in Organic Chemistry from the University of Illinois.